Dulanermin

度拉纳明

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDulanermin
Drug Alias Name度拉纳明DulanerminumDulanerminaDulanermineAMG-951 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonistsTumor necrosis factor receptor superfamily member 10A agonists
TargetsTumor necrosis factor receptor superfamily member 10BTumor necrosis factor receptor superfamily member 10A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen IncGenentech Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A